Human Normal Immunoglobulin

Human Normal Immunoglobulin (HNIG) is a medical substance derived from pooled plasma of healthy donors. It is a concentrated solution of antibodies that mimic the natural immune system’s defense against infections. HNIG is used to treat primary immunodeficiency disorders, such as agammaglobulinemia and hypogammaglobulinemia, where the body’s immune system is compromised.
In addition to immunodeficiency disorders, HNIG is also used to prevent and treat infections in patients with secondary immunodeficiencies, such as those undergoing chemotherapy or receiving organ transplants. It is also employed to treat certain autoimmune diseases, like idiopathic thrombocytopenic purpura (ITP), a condition characterized by low platelet counts due to autoantibodies.
HNIG is administered through intravenous infusion and is typically given every three to four weeks, depending on the patient’s condition and the specific indication for use. The treatment aims to increase the levels of immunoglobulins in the patient’s bloodstream, thereby enhancing their immune response and reducing the risk of infections.
HNIG is a safe and effective treatment option for eligible patients. However, monitor patients closely for any adverse reactions, such as allergic reactions or infusion-related side effects. Patients should inform their healthcare provider of any pre-existing conditions or allergies before receiving HNIG treatment.